The dual-control systems, incorporating PDAC-high affinity vehicles and the tumor-specific COX2 promoter, are expected to significantly reduce off-target effects and further enhance therapeutic efficacy, facilitating the advancement of ABTB2-targeted therapies toward clinical application. Here, PTGS2 is linked to neoplasm.